AZD6793

Phase 2

AstraZeneca PLC (AZN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

AZNPhase 2$256.5B

AZD6793 Phase 2 Est. Readout (PRESTO)

AZD6793• Chronic Obstructive Pulmonary Disease (COPD)987

Q3 2027~QEstimated

CT.gov

00%

Competitive Landscape

1 competitor in Chronic Obstructive Pulmonary Disease (COPD)

NVSIndacaterol 150 μg capsules

Phase 3

View Full Landscape

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial

NCT07082738

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Niraparib plus Abiraterone acetate plus PrednisonePhase 3

Metastatic Castration-resistant Prostate Cancer (mCRPC)

ChemotherapyPhase 3

Anticancer Treatment

AZD6234Phase 3

Obesity/Overweight

AZD1152Phase 3

Acute Myeloid Leukemia

Saruparib (AZD5305)Phase 3

Ovarian Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts